Silence Therapeutics (NASDAQ:SLN) Rating Reiterated by Morgan Stanley

Morgan Stanley restated their overweight rating on shares of Silence Therapeutics (NASDAQ:SLN) in a report issued on Monday, Benzinga reports. They currently have a $45.00 price target on the stock.

A number of other analysts have also weighed in on the company. HC Wainwright reissued a buy rating and set a $75.00 price objective on shares of Silence Therapeutics in a research note on Friday, March 15th. Chardan Capital increased their price target on shares of Silence Therapeutics from $26.00 to $42.00 and gave the company a buy rating in a research report on Thursday, March 14th. Finally, BMO Capital Markets initiated coverage on shares of Silence Therapeutics in a research report on Wednesday, January 31st. They issued an outperform rating and a $67.00 price objective on the stock.

Silence Therapeutics Stock Down 0.6 %

Silence Therapeutics stock opened at $22.50 on Monday. Silence Therapeutics has a 1-year low of $4.55 and a 1-year high of $27.72. The firm has a market capitalization of $673.38 million, a price-to-earnings ratio of -15.41 and a beta of 1.41. The company has a current ratio of 4.56, a quick ratio of 4.56 and a debt-to-equity ratio of 0.01. The firm has a 50 day simple moving average of $23.02 and a 200 day simple moving average of $17.25.

Silence Therapeutics (NASDAQ:SLN) last released its quarterly earnings results on Wednesday, March 13th. The company reported ($0.47) EPS for the quarter, missing analysts’ consensus estimates of ($0.25) by ($0.22). The firm had revenue of $2.61 million for the quarter, compared to analysts’ expectations of $11.46 million. Silence Therapeutics had a negative net margin of 171.41% and a negative return on equity of 262.17%. On average, analysts predict that Silence Therapeutics will post -1.38 earnings per share for the current year.

Hedge Funds Weigh In On Silence Therapeutics

A number of institutional investors have recently bought and sold shares of the stock. Vivo Capital LLC boosted its position in Silence Therapeutics by 116.7% during the 1st quarter. Vivo Capital LLC now owns 1,105,454 shares of the company’s stock valued at $23,878,000 after acquiring an additional 595,250 shares in the last quarter. Lynx1 Capital Management LP purchased a new position in shares of Silence Therapeutics in the 3rd quarter valued at approximately $2,315,000. Parkman Healthcare Partners LLC lifted its stake in shares of Silence Therapeutics by 20.8% in the 4th quarter. Parkman Healthcare Partners LLC now owns 232,942 shares of the company’s stock valued at $4,046,000 after purchasing an additional 40,063 shares during the period. Finally, SG Americas Securities LLC bought a new stake in shares of Silence Therapeutics during the fourth quarter valued at approximately $110,000. 98.73% of the stock is owned by institutional investors.

About Silence Therapeutics

Silence Therapeutics plc, a biotechnology company, focuses on the discovery and development novel molecules incorporating short interfering ribonucleic acid (siRNA) to inhibit the expression of specific target genes in hematology, cardiovascular, and rare diseases. The company's mRNAi GalNAc Oligonucleotide Discovery platform consists of precision engineered product candidates designed to target specific disease-associated genes in the liver.